M1FG
TGTX icon

Mach-1 Financial Group’s TG Therapeutics TGTX Stock Holding History

Mach-1 Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,484
Closed -$534K – 256
2023
Q2 		$534K Buy
+21,484
New +$555K 0.15% 129

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Mach-1 Financial Group's TGTX Position: Q3 2023 in Review

Mach-1 Financial Group sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 21,484 shares — an estimated $534K sold.

Mach-1 Financial Group first reported a position in TGTX in Q2 2023 and held it in 1 quarter. The position peaked at $534K in Q2 2023. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • Mach-1 Financial Group reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Mach-1 Financial Group sold 21,484 TG Therapeutics shares in Q3 2023, an estimated $534K.
  • Mach-1 Financial Group first reported a position in TG Therapeutics in Q2 2023 and held it in 1 quarter.
  • Mach-1 Financial Group's TG Therapeutics position peaked at $534K in Q2 2023.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on Mach-1 Financial Group's 13F filing for Q3 2023, filed 17 Oct 2023.